An extension to the companys Series A brings total funding to 23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infecti… [+5024 chars]
Read Full Story
German biotech Kupando raises €10M more to take its innate immunity drug into the clinic
Posted on March 18, 2026 at 